Estructuras impresas en 3D podrían acelerar la terapia de células CAR-T

Investigadores han desarrollado geles impresos en 3D que imitan los ganglios linfáticos para mejorar la producción de células CAR-T para el tratamiento del cáncer. Este enfoque aumentó las tasas de éxito y aceleró el crecimiento celular en comparación con los métodos estándar. Podría ayudar a reducir los costos y ampliar el acceso a la terapia en todo el mundo.

El proceso estándar para producir células CAR-T implica extraer células T de un paciente, modificarlas genéticamente con un virus para atacar el cáncer y multiplicarlas durante varias semanas. Esto puede costar más de 280.000 libras esterlinas por ronda y, a menudo, toma hasta un mes, lo que limita la disponibilidad, especialmente en países de bajos ingresos.

Artículos relacionados

Illustration of a German woman achieving complete remission from three autoimmune diseases via groundbreaking CAR-T therapy, symbolizing hope and medical triumph.
Imagen generada por IA

CAR-T therapy achieves complete remission of three autoimmune diseases in German woman

Reportado por IA Imagen generada por IA

A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.

Researchers have found that making cancer cells stiffer can enhance the effectiveness of car t-cell therapy against aggressive tumors. In experiments with mice, the approach led to complete tumor disappearance in some cases. The findings were presented recently at a conference in London.

Reportado por IA

A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.

Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.

Reportado por IA

Scientists at McMaster University and the Hospital for Sick Children in Canada have discovered that oligodendrocytes, cells typically supporting nerve function, aid the growth of glioblastoma by sending signals to tumor cells. Blocking this communication slowed tumor progression in lab models. The findings suggest an existing HIV drug, Maraviroc, could be repurposed for treatment.

Este sitio web utiliza cookies

Utilizamos cookies para análisis con el fin de mejorar nuestro sitio. Lee nuestra política de privacidad para más información.
Rechazar